Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01104155 · ClinicalTrials.gov registry record · Phase 2
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 2
- Development phase
- 123
- Enrollment target
NCT01104155 is a Phase 2 study that has completed, run by Eisai. The registered enrollment target is 123 participants.
The verdict
NCT01104155, a Phase 2 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 123 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, randomized study of two different dose regimens of eribulin mesylate in combination with intermittent erlotinib in patients with previously treated, advanced non-small cell lung cancer.
Interventions
- DRUG eribulin mesylate + erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2010-02-22 |
| Est. Completion | 2017-01-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01104155
The ClinicalTrials.gov registry entry for NCT01104155 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eribulin mesylate + erlotinib is the first listed.
NCT01104155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01104155 about?
NCT01104155 is a clinical study titled "Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer". This is a Phase 2, multicenter, randomized study of two different dose regimens of eribulin mesylate in combination with intermittent erlotinib in patients with previously treated, advanced non-small cell lung cancer.
What is the current status of trial NCT01104155?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2010-02-22. Estimated completion is 2017-01-18.
What interventions are being tested in trial NCT01104155?
The interventions under investigation include: eribulin mesylate + erlotinib (DRUG).
Who is sponsoring clinical trial NCT01104155?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.